[Federal Register Volume 68, Number 225 (Friday, November 21, 2003)]
[Notices]
[Page 65719]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-29070]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Orthopaedic and Rehabilitation Devices Panel of the Medical 
Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    Name of Committee: Orthopaedic and Rehabilitation Devices Panel of 
the Medical Devices Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on December 11, 2003, from 
8:30 a.m. to 6 p.m.
    Location: Holiday Inn, Walker/Whetstone Rooms, Two Montgomery 
Village Ave., Gaithersburg, MD.
    Contact Person: Janet L. Scudiero, Center for Devices and 
Radiological Health (HFZ-410), Food and Drug Administration, 9200 
Corporate Blvd., Rockville, MD 20850, 301-594-1184, ext. 176, or FDA 
Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in 
the Washington, DC area), code 12521. Please call the Information Line 
for up-to-date information on this meeting.
    Agenda: The committee will discuss, make recommendations, and vote 
on the reclassification of the intervertebral body fusion device (cage) 
intended for spinal fusion procedures in skeletally mature adults with 
degenerative disc disease at one or two levels from C2-C7 and L2-S1 
using autogenous bone graft. The device does not include combination 
products, such as the intervertebral body fusion device using 
morphogenic proteins and scaffolds. Background information for the 
topic, including the agenda and questions for the committee, will be 
available to the public no later than 1 business day before the meeting 
on the Internet at http://www.fda.gov/cdrh/panelmtg.html.
    Procedure: On December 11, 2003, from 9 a.m. to 6 p.m., the meeting 
is open to the public. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Written submissions may be made to the contact person by 
December 1, 2003. Oral presentations from the public will be scheduled 
between approximately 11:45 a.m. and 12:45 p.m. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before December 1, 2003, 
and submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
    Closed Committee Deliberations: On December 11, 2003, from 8:30 
a.m. to 9 a.m., the meeting will be closed to permit FDA to present to 
the committee trade secret and/or confidential commercial information 
regarding pending and future device issues. This portion of the meeting 
will be closed to permit discussion of this information (5 U.S.C. 
552b(c)(4)).
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Shirley Meeks, 
Conference Management Staff, at 301-594-1283, ext. 105, at least 7 days 
in advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: November 14, 2003.
William K. Hubbard,
Associate Commissioner for Policy and Planning.
[FR Doc. 03-29070 Filed 11-20-03; 8:45 am]
BILLING CODE 4160-01-S